July 26th 2024
Minimizing protocol deviations is a simple, yet effective way for sites to keep trials patient-centric.
DIA's Objectives for the Remainder of 2024
July 25th 2024In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.
Results from an induction trial and maintenance trial show Skyrizi (risankizumab) improved endoscopic and histological secondary outcomes characterized by endoscopic improvement, remission, and histological, endoscopic, and mucosal improvements in patients with moderately to severely active ulcerative colitis.
Themes Involving Clinical Trials at the 2024 DIA Global Annual Meeting
July 24th 2024In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.
DIA Global Head of Growth Highlights Variety of Sessions at the 2024 Global Annual Meeting
July 23rd 2024Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.
Paxlovid Postexposure Prophylaxis Not Found to Significantly Lower Risk of Symptomatic SARS-CoV-2
Paxlovid was the first oral drug approved by the FDA to treat Covid-19 in adults who do not require supplemental oxygen and who have an increased risk of progression to severe disease.
Altuviiio Shows Sustained Protection Against Bleeding Episodes in Children with Severe Hemophilia A
Altuviiio is a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes in adults and children with hemophilia.
Novel Anti-CD38 Targeted Therapy Shows Promise Treating Immune Thrombocytopenia in Phase II Trial
In a Phase I-II trial, CM313 was found to inhibit antibody-dependent cell-mediated cytotoxicity on platelets while achieving long-term efficacy in patients with immune thrombocytopenia.